Aug 26, 2022
- CO
- CT
- IN
- KY
- ME
- MO
- NH
- NV
- OH
- VA
- WI
- CA
- GA
UPDATE: New Gene Therapy Solution offers ASO groups protection from unknown risk. Newly-approved Zynteglo added
Register now to join our live webinar at noon (ET), Wednesday, September 14. You’ll be able to ask our experts how our new Gene Therapy Solution can protect your administrative services only (ASO) National and Large Group clients from financial risks related to breakthrough gene therapies. A single gene-therapy claim can reach up to $3 million.
This solution will provide 100% protection from the drug claims for Luxturna, Zolgensma and Zynteglo. These are emerging clinical treatments with the potential to be highly effective in treating rare conditions like Spinal Muscular Atrophy or Retinal Dystrophy with a one-time or a finite number of treatments. Quoting starts in September 2022 for groups with January 1, 2023, effective dates.
This solution will be available for new or existing National Accounts and Large Group ASO commercial clients as a provision of Anthem Stop Loss except for Balanced Funding, Cost Plus, and Minimum Premium Plan (MPP) arrangements. We will offer a stop loss policy that only covers gene therapy drug costs to National Accounts and Large Group ASO commercial clients with over 20,000 subscribers who do not have Anthem Stop Loss or Stop Loss with any other vendor.
We will evaluate other gene therapies for coverage as they come to market. You can learn about Gene Therapy drugs that the FDA may approve in the IngenioRx Pipeline Report.
Please contact your sales representative for more information.